While neuroinflammation or other adverse responses to the therapeutic agent could also explain this unfortunate outcome, one must consider the possibility of a dominant negative effect and therefore interpret the observed worsening of HD clinical manifestation as the consequences of lowered total HTT protein levels in HD patients, resulting in accelerated HD progression. The gene discussed is HTT; the disease is Huntington disease.